The DOI matches its Crossref record; 259 of the 259 references it cites were found in a registry or an index.
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Open accessAbstract
Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)‐modified T cells can induce durable remissions in patients with refractory B‐lymphoid cancers. By contrast, results applying CAR‐modified T cells to solid malignancies have been comparatively modest. Alternative strategies to redirect T cell specificity and cytolytic function are therefore necessary if ACT is to serve a greater role in human cancer treatments. T cell receptors (TCRs) are antigen recognition structures physiologically expressed by all T cells that have complementary, and in some cases superior, properties to CARs. Unlike CARs, TCRs confer recognition to epitopes derived from proteins residing within any subcellular compartment, including the membrane, cytoplasm and nucleus. This enables TCRs to detect a broad universe of targets, such as neoantigens, cancer germline antigens, and viral oncoproteins. Moreover, because TCRs have evolved to efficiently detect and amplify antigenic signals, these receptors respond to epitope densities many fold smaller than required for CAR‐signaling. Herein, we summarize recent clinical data demonstrating that TCR‐based immunotherapies can mediate regression of solid malignancies, including immune‐checkpoint inhibitor refractory cancers. These trials simultaneously highlight emerging mechanisms of TCR resistance. We conclude by discussing how TCR‐based immunotherapies can achieve broader dissemination through innovations in cell manufacturing and non‐viral genome integration techniques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–259 of 259
CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Davenport, A. J., Jenkins, M. R., Cross, R. S., Yong, C. S. M., Prince, H. M., Ritchie, D. S., Trapani, J. A., Kershaw, M. H., Darcy, P. K., & Neeson, P. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0048 · Cited by 164
Chapuis, A. G., Thompson, J. A., Margolin, K. A., Rodmyre, R., Lai, I. P., Dowdy, K., Farrar, E. A., Bhatia, S., Sabath, D. E., Cao, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113748109 · Cited by 163
RNA editing derived epitopes function as cancer antigens to elicit immune responses
Zhang, M., Fritsche, J., Roszik, J., Williams, L. J., Peng, X., Chiu, Y., Tsou, C., Hoffgaard, F., Goldfinger, V., Schoor, O., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06405-9 · Cited by 162
Chinnasamy, N., Wargo, J. A., Yu, Z., Rao, M., Frankel, T. L., Riley, J. P., Hong, J. J., Parkhurst, M. R., Feldman, S. A., Schrump, D. S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001775 · Cited by 161
Signaling and Polarized Communication Across the T Cell Immunological Synapse
Dustin, M. L., & Choudhuri, K. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100814-125330 · Cited by 158
Lo, W., Parkhurst, M., Robbins, P. F., Tran, E., Lu, Y.-C., Jia, L., Gartner, J. J., Pasetto, A., Deniger, D., Malekzadeh, P., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0686 · Cited by 158
Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
Xiong, W., Chen, Y., Kang, X., Chen, Z., Zheng, P., Hsu, Y.-H., Jang, J. H., Qin, L., Liu, H., Dotti, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.020 · Cited by 157
Deniger, D. C., Pasetto, A., Robbins, P. F., Gartner, J. J., Prickett, T. D., Paria, B. C., Malekzadeh, P., Jia, L., Yossef, R., Langhan, M. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0573 · Cited by 157
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156
Self-citationForget, M., Haymaker, C., Hess, K. R., Meng, Y. J., Creasy, C. A., Karpinets, T. V., Fulbright, O. J., Roszik, J., Woodman, S. E., Kim, Y. U., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3649 · Cited by 143
Slaga, D., Ellerman, D. A., Lombana, T. N., Vij, R., Li, J., Hristopoulos, M. L., Clark, R., Johnston, J., Shelton, A., Mai, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat5775 · Cited by 137
Qin, H., Cho, M., Haso, W. M., Zhang, L., Tasian, S. K., Oo, H. Z., Negri, G. L., Lin, Y., Zou, J., Mallon, B. S., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612903 · Cited by 133
Davis, J. L., Theoret, M. R., Zheng, Z., Lamers, C. H. J., Rosenberg, S. A., & Morgan, R. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1280 · Cited by 132
Rejection of immunogenic tumor clones is limited by clonal fraction
Gejman, R. S., Chang, A. Y., Jones, H. F., DiKun, K. M., Hakimi, A. A., Schietinger, A., & Scheinberg, D. A. (2018) · eLife · doi:10.7554/elife.41090 · Cited by 129
Zhang, T., Barber, A., & Sentman, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0130 · Cited by 128
Veatch, J. R., Lee, S. M., Fitzgibbon, M., Chow, I., Jesernig, B. L., Schmitt, T., Kong, Y., Kargl, J., Houghton, A. M., Thompson, J. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98689 · Cited by 127
Sommermeyer, D., & Uckert, W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902055 · Cited by 126
Molecular architecture of the αβ T cell receptor–CD3 complex
Birnbaum, M. E., Berry, R., Hsiao, Y., Chen, Z., Shingú-Vázquez, M., Yu, X., Waghray, D., Fischer, S., McCluskey, J., Rossjohn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420936111 · Cited by 126
Parkhurst, M. R., Joo, J. S., Riley, J. P., Yu, Z., Li, Y., Robbins, P. F., & Rosenberg, S. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1638 · Cited by 126
Niederman, T. M. J., Ghogawala, Z., Carter, B. S., Tompkins, H. S., Russell, M. M., & Mulligan, R. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092562399 · Cited by 125
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities
Roybal, K. T., & Lim, W. A. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052302 · Cited by 124
van den Berg, J. H., Gomez, R., van de Wiel, B. A., Hulshoff, L., van den Broek, D. A., Bins, A. D., Tan, H. L., Harper, J. V., Hassan, N. J., Jakobsen, B. K., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.60 · Cited by 124
Smith, E. L., Stæhr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.016 · Cited by 122
Rycaj, K., Plummer, J. B., Yin, B., Li, M., Garza, J. G., Radvanyi, L. G., Ramondetta, L. M., Lin, K., Johanning, G. L., Tang, D. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0388 · Cited by 121
CD3 limits the efficacy of TCR gene therapy in vivo
Ahmadi, M., King, J. P., Xue, S., Voisine, C., Holler, A., Wright, G. P., Waxman, J., Morris, E. C., & Stauss, H. J. (2011) · Blood · doi:10.1182/blood-2011-04-346338 · Cited by 121
Beane, J. D., Lee, G., Zheng, Z., Mendel, M. C., Abate‐Daga, D., Bharathan, M., Black, M. A., Gandhi, N. H., Yu, Z., Chandran, S. S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.71 · Cited by 116
Self-citationDunn, S. M., Rizkallah, P. J., Baston, E., Mahon, T., Cameron, B., Moysey, R. K., Gao, F., Sami, M., Boulter, J. M., Li, Y., et al. (2006) · Protein Science · doi:10.1110/ps.051936406 · Cited by 112
Nowicki, T. S., Berent-Maoz, B., Cheung-Lau, G. C., Huang, R., Wang, X., Tsoi, J., Kaplan‐Lefko, P. J., Cabrera, P. V., Tran, J., Pang, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3496 · Cited by 106
Molecular Design of the Cαβ Interface Favors Specific Pairing of Introduced TCRαβ in Human T Cells
Voss, R.-H., Willemsen, R. A., Kuball, J. H. E., Grabowski, M., Engel, R., Intan, R. S., Guillaume, P., Romero, P. J., Huber, C. H., & Theobald, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.391 · Cited by 103
Chapuis, A. G., Afanasiev, O. K., Iyer, J. G., Paulson, K. G., Parvathaneni, U., Hwang, J. H., Lai, I. P., Roberts, I. M., Sloan, H. L., Bhatia, S., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0087 · Cited by 103
Vaccines to Prevent Infections by Oncoviruses
Schiller, J. T., & Lowy, D. R. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134019 · Cited by 101
Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
Rothermel, L. D., Sabesan, A. C., Stephens, D. J., Chandran, S. S., Paria, B. C., Srivastava, A. K., Somerville, R. P. T., Wunderlich, J. R., Lee, C. R., Xi, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2294 · Cited by 99
Self-citationA soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties.
Novotný, J., Ganju, R. K., Smiley, S. T., Hussey, R. E., Luther, M., Recny, M. A., Siliciano, R. F., & Reinherz, E. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8646 · Cited by 97
TET2 in Normal and Malignant Hematopoiesis
Bowman, R. L., & Levine, R. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026518 · Cited by 94
Polyfunctional response by Imm TAC ( IMC gp100) redirected CD 8 + and CD 4 + T cells
Boudousquié, C., Bossi, G., Hurst, J. M., Rygiel, K. A., Jakobsen, B. K., & Hassan, N. J. (2017) · Immunology · doi:10.1111/imm.12779 · Cited by 94
Haga-Friedman, A., Horovitz‐Fried, M., & Cohen, C. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103020 · Cited by 89
Chapuis, A. G., Lee, S. M., Thompson, J. A., Roberts, I. M., Margolin, K. A., Bhatia, S., Sloan, H. L., Lai, I. P., Wagener, F. D., Shibuya, K. C., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20152021 · Cited by 89
PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
Bowers, J. S., Majchrzak, K., Nelson, M. H., Aksoy, B. A., Wyatt, M. M., Smith, A. S., Bailey, S. R., Neal, L. R., Hammerbacher, J., & Paulos, C. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01221 · Cited by 89
Stromnes, I. M., Blattman, J. N., Tan, X., Jeevanjee, S., Gu, H., & Greenberg, P. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41991 · Cited by 87
Sebestyén, Z., Schooten, E., Sals, T., Zaldívar, I., José, E. S., Alarcón, B., Bobisse, S., Rosato, A., Szöllõsi, J., Gratama, J. W., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7736 · Cited by 82
Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition
Bialer, G., Horovitz‐Fried, M., Ya’acobi, S., Morgan, R. A., & Cohen, C. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902047 · Cited by 81
Functional three-domain single-chain T-cell receptors.
Chung, S., Wucherpfennig, K. W., Friedman, S., Hafler, D. A., & Strominger, J. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12654 · Cited by 75
Kerkar, S. P., Wang, Z.-F., Lasota, J. P., Park, T. S., Patel, K. J., Groh, E. M., Rosenberg, S. A., & Miettinen, M. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000119 · Cited by 74
Domain-swapped T cell receptors improve the safety of TCR gene therapy
Bethune, M. T., Gee, M. H., Bunse, M., Lee, M. S., Gschweng, E. H., Pagadala, M. S., Zhou, J., Cheng, D., Heath, J. R., Kohn, D. B., et al. (2016) · eLife · doi:10.7554/elife.19095 · Cited by 73
Border, E. C., Sanderson, J. P., Weissensteiner, T., Gerry, A. B., & Pumphrey, N. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1532759 · Cited by 70
Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.195 · Cited by 69
Long-Term Depletion of Naive T Cells in Patients Treated for Hodgkin's Disease
Watanabe, N., Rosa, S. C. D., Cmelak, A. J., Hoppe, R. T., Herzenberg, L. A., Herzenberg, L. A., & Roederer, M. (1997) · Blood · doi:10.1182/blood.v90.9.3662 · Cited by 68
Shared cancer neoantigens: Making private matters public
Klebanoff, C. A., & Wolchok, J. D. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20172188 · Cited by 67
Self-citationTumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy
Turcotte, S., Gros, A., Tran, E., Lee, C. R., Wunderlich, J. R., Robbins, P. F., & Rosenberg, S. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1736 · Cited by 65
Hanada, K., Perry-Lalley, D. M., Ohnmacht, G. A., Bettinotti, M. P., & Yang, J. C.-H. (2001) · PubMed · Cited by 63
Targeting human melanoma neoantigens by T cell receptor gene therapy
Leisegang, M., Kammertoens, T., Uckert, W., & Blankenstein, T. J. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83465 · Cited by 63
Opportunities and challenges for TCR mimic antibodies in cancer therapy
Chang, A. Y., Gejman, R. S., Brea, E. J., Oh, C. Y., Mathias, M. D., Pankov, D., Casey, E. R., Dao, T., & Scheinberg, D. A. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1176138 · Cited by 62
Dadmarz, R., Sgagias, M. K., Rosenberg, S. A., & Schwartzentruber, D. J. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01517229 · Cited by 57
Antibody Targeting to a Class I MHC-Peptide Epitope Promotes Tumor Cell Death
Wittman, V., Woodburn, D., Nguyen, T. T. M., Neethling, F. A., Wright, S. E., & Weidanz, J. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.4187 · Cited by 55
Voss, R.-H., Thomas, S., Pfirschke, C., Hauptrock, B., Klobuch, S., Kuball, J. H. E., Grabowski, M., Engel, R., Guillaume, P., Romero, P. J., et al. (2010) · Blood · doi:10.1182/blood-2009-11-254078 · Cited by 54
Verma, B., Jain, R., Caseltine, S. L., Rennels, A. D., Bhattacharya, R., Markiewski, M. M., Rawat, A. K., Neethling, F. A., Bickel, U., & Weidanz, J. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002376 · Cited by 34
Yao, X., Lu, Y., Parker, L. L., Li, Y. F., El‐Gamil, M., Black, M. A., Xu, H., Feldman, S. A., van der Bruggen, P., Rosenberg, S. A., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000123 · Cited by 34
Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection
Albers, J. J., Ammon, T., Gosmann, D., Audehm, S., Thoene, S., Winter, C., Secci, R., Wolf, A. A., Stelzl, A., Steiger, K., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900367 · Cited by 25
Williams, C. M., Schonnesen, A. A., Zhang, S.-Q., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00894 · Cited by 14
Cited by
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Self-citationNeoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
Metadata
- Authors
- Chandran, S. S., & Klebanoff, C. A.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2019-07
- Volume
- 290
- Issue
- 1
- Pages
- 127-147
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2966041852
- Cited by
- 323
- References
- 259
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.